NDC 70860-225
Bortezomib
Bortezomib
Bortezomib is a Intravenous; Subcutaneous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Athenex Pharmaceutical Division, Llc.. The primary component is Bortezomib.
Product ID | 70860-225_49aeb918-1016-4748-aa7a-53c51014e650 |
NDC | 70860-225 |
Product Type | Human Prescription Drug |
Proprietary Name | Bortezomib |
Generic Name | Bortezomib |
Dosage Form | Injection, Powder, Lyophilized, For Solution |
Route of Administration | INTRAVENOUS; SUBCUTANEOUS |
Marketing Start Date | 2022-05-06 |
Marketing Category | ANDA / |
Application Number | ANDA210824 |
Labeler Name | Athenex Pharmaceutical Division, LLC. |
Substance Name | BORTEZOMIB |
Active Ingredient Strength | 4 mg/1 |
Pharm Classes | Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |